Lyell Immunopharma Inc. (NASDAQ:LYEL) price closed lower on Monday, September 13, dropping -10.58% below its previous close.
A look at the daily price movement shows that the last close reads $17.95, with intraday deals fluctuated between $13.2503 and $17.75. Taking into account the 52-week price action we note that the stock hit a 52-week high of $19.84 and 52-week low of $13.11. The stock added 12.39% on its value in the past month.
Lyell Immunopharma Inc., which has a market valuation of $3.61 billion. Analysts tracking LYEL have forecast the quarterly EPS to shrink by -0.27 per share this quarter, while the same analysts predict the annual EPS to hit -$1.43 for the year 2021 and up to -$1.29 for 2022.
On average, analysts have forecast the company’s revenue for the quarter will hit $2.3 million, with the likely lows of $2 million and highs of $2.6 million. Staying with the analyst view, there is a consensus estimate of $10.12 million for the company’s annual revenue in 2021.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews.
The overview shows that LYEL’s price is at present 1.59% off the SMA20 and 3.09% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 50.31, with weekly volatility standing at 17.30%. The indicator jumps to 9.23% when calculated based on the past 30 days. Lyell Immunopharma Inc. (NASDAQ:LYEL)’s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 1.52.
An analysis of the Lyell Immunopharma Inc. (NASDAQ:LYEL) stock in terms of its daily trading volume indicates that the 3-month average is 472.26K.
Current records show that the company has 242.83M in outstanding shares. The insiders’ percentage holdings are 2.70% of outstanding shares while the percentage share held by institutions stands at 31.10%. But the -4.97% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.